Hewlett-Packard Company Announces Early Tender Results for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Hewlett-Packard Company Announces Early Tender Results for Cash Tender Offers

PALO ALTO, CA--(Marketwired - Oct 14, 2015) - Hewlett-Packard Company ("HP Co.") ( NYSE : HPQ ) today announced the early tender results as of 5:00 p.m. New York City time on October 14, 2015 (the "Early Tender Deadline") for its previously announced cash tender offers (collectively, the "Tender Offers") to purchase outstanding debt securities of HP Co. set forth in the tables below (collectively, the "Notes" and each a "series" of Notes).

The complete terms of the Tender Offers are set forth in two separate offers to purchase, one of which sets forth the terms of a tender offer for any and all of the outstanding Notes set forth in Table I (the "Any and All Tender Offer"), and one of which sets forth the terms of a tender offer for the outstanding Notes set forth in Table II (the "Waterfall Tender Offer") up to a combined aggregate principal amount equal to $2,300,000,000 (the "Waterfall Maximum Amount"), subject to certain acceptance priority levels specified in Table II, and related letters of transmittal, each of which are dated September 30, 2015.

The principal amount of each series of Notes that were validly tendered and not validly withdrawn in the Tender Offers as of the Early Tender Deadline is set forth in the tables below.

Table I - Any and All Tender Offer

Title of Security   CUSIP Number   Aggregate Principal Amount Outstanding   Aggregate Principal Amount Tendered   Percent of Amount Outstanding Tendered
2.200% Notes due Dec. 2015   428236BE2   $650,000,000   $340,549,000   52.39%
2.650% Notes due June 2016   428236BL6   $1,000,000,000   $653,557,000   65.36%
3.000% Notes due Sept. 2016   428236BP7   $1,300,000,000   $868,394,000   66.80%
3.300% Notes due Dec. 2016   428236BU6   $850,000,000   $627,772,000   73.86%
5.40% Notes due March 2017   428236AM5   $500,000,000   $337,265,000   67.45%
2.600% Notes due Sept. 2017   428236BW2   $1,500,000,000   $1,062,730,000   70.85%
5.50% Notes due March 2018   428236AS2   $750,000,000   $458,905,000   61.19%
                 

Table II - Waterfall Tender Offer

Title of Security   CUSIP Number   Aggregate Principal Amount Outstanding Acceptance Priority Level Aggregate Principal Amount Tendered   Percent of Amount Outstanding Tendered   Approximate Proration Factor
2.750% Notes due Jan. 2019   428236BY8   $1,250,000,000 1 $950,206,000   76.02%   100%
Floating Rate Notes due Jan. 2019   428236BZ5   $750,000,000 2 $648,367,000   86.45%   100%
3.750% Notes due Dec. 2020   428236BF9   $1,350,000,000 3 $836,013,000   61.93%   84%
4.300% Notes due June 2021   428236BM4   $1,250,000,000 4 $818,393,000   65.47%   0%
4.375% Notes due Sept. 2021   428236BQ5   $1,000,000,000 5 $646,041,000   64.60%   0%
4.650% Notes due Dec. 2021   428236BV4   $1,500,000,000 6 $885,588,000   59.04%   0%
4.050% Notes due Sept. 2022   428236BX0   $500,000,000 7 $214,458,000   42.89%   0%
6.000% Notes due Sept. 2041   428236BR3   $1,200,000,000 8 $781,272,000   65.11%   0%

Subject to the terms and conditions of the Any and All Tender Offer, HP Co. expects that it will accept for purchase any and all Notes listed on Table I validly tendered and not validly withdrawn prior to the Early Tender Deadline. Subject to the terms and conditions of the Waterfall Tender Offer, HP Co. expects that it will accept for purchase Notes listed on Table II validly tendered and not validly withdrawn prior to the Early Tender Deadline in a combined aggregate principal amount equal to $2,300,000,000 (the "Waterfall Maximum Amount"). 

The settlement for the Notes accepted by HP Co. in connection with the Early Tender Deadline is currently expected to take place on October 16, 2015 (the "Settlement Date"). The Notes tendered pursuant to the Tender Offers may no longer be withdrawn, unless otherwise required by law.

The Tender Offers will expire at 11:59 p.m., New York City time, on October 28, 2015, unless extended (such date and time, as the same may be extended, the "Expiration Time").

Since the Waterfall Tender Offer was oversubscribed as of the Early Tender Deadline, the amounts of each series of Notes listed on Table II that are purchased in the Waterfall Tender Offer on the Settlement Date will be determined in accordance with the acceptance priority levels and the proration procedures described in the offer to purchase in connection with the Waterfall Tender Offer. HP Co. expects to return any Notes tendered but not accepted for purchase on October 16, 2015.

The Tender Offers are not conditioned upon any minimum amount of Notes being tendered, and the Tender Offers may be amended, extended, terminated or withdrawn in whole or with respect to one or more series of Notes. 

HP Co.'s obligation to accept for purchase, and to pay for, any Notes validly tendered (and not validly withdrawn) and accepted for purchase pursuant to the Tender Offers are conditioned upon the satisfaction or waiver of the conditions described in each applicable offer to purchase under the heading "Terms of the Tender Offer--Conditions to the Tender Offer."

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The Tender Offers are being made solely pursuant to terms and conditions set forth in the applicable offer to purchase and the applicable letter of transmittal.

Goldman, Sachs & Co., Morgan Stanley & Co. LLC and HSBC Securities (USA) Inc. are serving as Dealer Managers for the Tender Offers. Questions regarding the Tender Offers may be directed to Goldman, Sachs & Co. at (800) 828-3182 (toll free) or (212) 357-0422 (collect), to Morgan Stanley & Co. LLC at (800) 624-1808 (toll free) or (212) 761-1057 (collect) or to HSBC Securities (USA) Inc. at (888) HSBC-4LM (toll free) or (212) 525-5552 (collect). Requests for the offers to purchase or the letters of transmittal or the documents incorporated by reference therein may be directed to Global Bondholder Services Corporation, which is acting as Tender and Information Agent for the Tender Offer, at the following telephone numbers: banks and brokers, (212) 430-3774; all others toll free at (866) 924-2200.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of HP Co. may differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to any statements regarding the Tender Offers, any statements of expectation or belief and any statements or assumptions underlying any of the foregoing. Risks, uncertainties and assumptions include the possibility that expected benefits may not materialize as expected and other risks that are described in HP Co.'s Annual Report on Form 10-K for the fiscal year ended October 31, 2014 and HP Co.'s other filings with the Securities and Exchange Commission, including HP Co.'s Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2015. HP Co. assumes no obligation and does not intend to update these forward-looking statements.

Editorial contacts Kait Conetta HP corpmediarelations@hp.com www.hp.com/go/newsroom

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading